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ABSTRACT   
BACKGROUND 
Survival rates of South African children with osteosarcoma (OS) are known to be poor but 
prognostic factors have not been elucidated in an African setting. 
AIM AND SETTING 
To determine the overall survival rate and prognostic factors in children with OS at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH). 
METHODS 
A retrospective review was conducted of children with OS from 1990 to 2010. Descriptive 
statistics, Kaplan-Meier survival analysis and Cox logistic regression were performed. 
RESULTS 
55 files were available for analysis. The median symptom duration was 90 days. The median 
age was 12.1years. The majority had poor prognostic features: 47 (85%) had masses larger 
than 8cm diameter, all patients had high alkaline phosphatase and 46 (83.6%) had elevated 
lactate dehydrogenase (LDH). Histology included osteoblastic (37/55) and chondroblastic OS 
(9/55). Forty-three (78.2%) patients had low BMI at presentation. Forty-one patients were 
treated with ifosfamide, doxorubicin, methotrexate and cisplatinum and one patient was on a 
hybrid protocol. Thirteen (25%) did not receive chemotherapy and four patients declined 
surgery. The five-year survival rate of those treated with curative intent was 42%. Causes of 
death included progression of disease (22/42) and treatment complications (5/42). On 
univariate analysis site of primary tumour (p = 0.044), LDH (p = 0.011) and stage (p = 
0.0001) impacted on survival, while on multivariate analysis confirmed only stage 
(p=0.0001) and unknown LDH level (p= 0.011) as significant. 
CONCLUSION 
Advanced disease at presentation, which is a modifiable factor, was common and impacted 
negatively on overall survival.  
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Introduction 
Primary bone tumours represent the third most frequent group of malignancies in adolescents 
and young adults, after leukaemia and lymphomas 
(1,2,3,4,5)
 Osteosarcoma (OS) is the most 
common bone malignancy in adolescents. This tumour is more common in black than in 
white patients, and has a higher incidence in males 
(3)
. 
Survival rates of osteosarcoma in high income countries range from 60 to 80% 
(2, 3,4)
. 
Successful treatment requires a combination of multi-agent chemotherapy and complete 
surgical excision of the tumour. This data originates from studies done in well-resourced 
centres 
(3) 
and there is a paucity of data from low and middle income settings. Current 
survival rates reported from South Africa range from 7.5% in a study done in Ga-rankuwa 
(6) 
to 30% in Bloemfontein 
(7)
. 
This poor survival rate is postulated to be due to advanced disease at presentation, among 
other factors, which may be related to delays in diagnosis 
(,4,5,6)
.   In South Africa, patients 
with osteosarcoma may present rather later than in well-resourced countries. Due to several 
reasons, among them suboptimal access to health care, these patients may seek medical 
attention only when a large mass has ulcerated or is constantly oozing fluid and requires 
medical attention
 (2) 
. 
In studies from high income countries factors shown to have prognostic significance include 
sex, site of primary tumour, size of tumour, levels of non-specific tumour markers lactate 
dehydrogenase and alkaline phosphatase. In addition, presence of pulmonary and/or bone 
metastases, extent of necrosis after pre-operative chemotherapy and histological subtype 
affect outcome 
(2,4,11,12,13)
. 
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The patients who survive face devastating effects from the treatment, as most aggressive 
chemotherapy protocols are associated with severe, often long-term side effects, such as 
hearing impairment, cardiotoxicity and infertility
 (3, 15)
. In high income countries amputation 
has become a rarity in the treatment of this disease 
(3)
, while in South Africa this modality is 
still standard of care
(6, 8)
. 
Numerous studies have addressed the issue of delay in diagnosis and whether this contributes 
to poorer outcomes in children with cancer 
(11, 12,13,14)
. However, all these studies originate in 
high income countries, and this issue has not been satisfactorily addressed in an African 
setting. This study aims, in part, to contribute to this small but growing body of knowledge. 
 
 Aims and objectives 
The aim of the study was to characterise the demographics and tumour characteristics of a 
paediatric population with osteosarcoma in Johannesburg and to determine modifiable and 
non-modifiable prognostic factors.  Five-year survival rate and causes of death were 
described.  
Research methods and design 
The study is a retrospective folder review of paediatric patients with OS treated at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) between 1 January 1990 and 31 
December 2010. The Paediatric Oncology Unit at CMJAH is a tertiary referral centre in an 
urban area accepting patients from a wide drainage area in Gauteng, other areas of South 
Africa as well as neighbouring African states. All children with histological confirmed OS 
under the age of 18 during the study period were included. Folders with substantially 
incomplete records were excluded. This included patients for whom no records existed, those 
whose histology results were unavailable and those who completed treatment in other centres. 
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Descriptive statistical methods were used to characterise demographics (age, sex, ethnicity 
and Human Immunodeficiency Virus [HIV] infection), duration of symptoms and nutritional 
status at presentation. A body mass index (BMI) <18 was used as a marker for the ‘under-
nutrition’ indicator (12). The duration of presenting symptoms was recorded according to 
history given by the primary caregiver noted in the folders. This was determined from the 
date of first presentation with disease-specific symptoms to the first date seen in the 
paediatric oncology unit or orthopaedic unit at CMJAH. 
Enneking stage I and II tumours were defined as localised disease while stage III tumours 
were classified as metastatic disease 
(1).
  
 
Table 1: The Enneking staging system for skeletal malignancies 
Stage Tumour grade Tumour size 
IA Low <8cm 
IB Low >8cm 
IIA High <8cm 
IIB High >8cm 
III Any tumour grade skip 
metastases 
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All histological specimens were reviewed to determine extent of post chemotherapy necrosis. 
Ninety five percent (95%) tumour necrosis post chemotherapy was regarded as favourable 
response to chemotherapy
 (1,4,10)
. Serum Alkaline phosphatase level was used as a marker of 
disease. A cut off level for different ages was used. ALP> 1.5 of normal was regarded as 
significantly high. (Normal ranges: Age two to 10 years 420IU/L. For the ages 10 to 11years 
560 IU/L; 12 to 15 years male:  495IU/L; 12 to 13 years female: 420IU/L and 14 to 15 years 
female: 230IU/L (see Table below). Reference ranges for LDH in this population was 140 
IU/L to 280IU/L.  
Table 2: Normal Alkaline phosphatase ranges for sex and age 
Age in years Range 
2 -10 420 IU/L 
10-11 560 IU/L 
12-15 MALES 495 IU/L 
12-13 FEMALES 420 IU/L 
14-15 FEMALES 230 IU/L 
 
Means with standard deviations were employed for normally distributed data and medians 
with interquartile ranges (IQR) for non-parametric data were calculated. Five-year actuarial 
survival was calculated using the Kaplan-Meier method. Prognostic factors were determined 
with Cox regression analysis and a p value of <0.05 was considered statistically significant. 
Multivariate logistic regression analysis of variables associated with mortality using Cox 
proportional hazard model was also performed. Ethical approval was obtained from the 
University of Witwatersrand Human Research Ethics Committee for the study (Ethics 
Number: M170492).  
 
 
 
 
 
14 
Results 
Over the 20 year period a total of 1941 patients were diagnosed with malignancies, 65 (3.3%) 
of whom had osteosarcoma. Ten files were excluded from the study as records were 
substantially incomplete, thus 55 files were available for evaluation. 
 
Patient characteristics 
Twenty-seven (49%) patients were male and twenty-eight (51%) were female. The median 
age at presentation was 12.1 years (IQR: 9.75 years to 14 years). The youngest patient was 
2.8 years old. A minority of patients (12/55, 22%) were of healthy weight while most 
children (43/55, 78%) were underweight at presentation, with a BMI <18. It was not 
documented whether these patients were underweight due to cachexia or malnutrition. Forty 
patients had documented HIV negative results. Fifteen were unknown prior to 1994 as there 
was no routine HIV treatment programme at CMJAH. 
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FIGURE1: Population diagnosed with osteosarcoma at CMJAH 
Osteogenic sarcoma (n=65) 
Excluded (n=10) 
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Table 3: Characteristics of children with osteosarcoma at CMJAH 
 Variable  Number of patients n =55 Percentage 
DEMOGRAPHICS 
    Sex   
        Male 27 49 
        Female 28 51 
    HIV   
        Negative 40 72.7 
        Positive 0 0 
        Unknown 15 27.3 
    Race   
        Black 40 72.7 
        White 8 14.6 
        Mixed ancestry 6 10.9 
        Asian 1 1.8 
    Body mass index 
(BMI) 
  
        BMI>18 12 21.8 
        BMI<18 43 78.2 
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The median duration of disease-specific symptoms was 90 days (IQR: 60 to 120 days) with 
the longest recorded duration of 180 days. One patient had Li-Fraumeni syndrome (LFS) 
known to predispose to the development of osteosarcoma. Forty-one patients were treated on 
combination chemotherapy consisting of methotrexate (cumulative dose 96mg/m
2
), 
doxorubicin (350mg/m
2
), cisplatin (360mg/m
2
) and ifosfamide (5400mg/m
2
). The patient 
with LFS was treated on a hybrid protocol as she had previously been treated for multiple 
malignancies. Thirteen patients did not receive any curative therapy: six patients declined 
treatment for reasons such as fear of mutilation and cultural barriers to amputation and seven 
patients presented with advanced disease and were palliated. Twenty-nine patients (52.7%) 
presented with localised disease while 26 (47.3%) presented with metastatic disease. Two 
patients in the study had palliative amputations. Of the forty-two who had curative surgery, 
thirty-five patients had amputations and seven underwent limb salvage procedures. (See table 
4) 
Response to treatment  
Forty-two patients were treated with curative intent. Twenty-six of the 42 who received 
chemotherapy had more than 95% necrosis documented in response to treatment, and were 
deemed to be in remission (see table 4). 
Four (9.5%) patients developed dilated cardiomyopathy secondary to the use of doxorubicin. 
These four patients, treated in the 1990’s all received doses higher ranging between 
375mg/m
2 
and 530mg/m
2
. Further toxicities were not analysed in this series. 
Sites of relapse included local in four patients, distal in three patients and undocumented in 
four patients.  
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Table 4: Tumour characteristics   
Variable Number of 
patients 
Percentage 
Treatment 
   Chemotherapy 42 76.3 
   *No 
Chemotherapy 
13 23.6 
         Palliation 7 53.8 
         Declined 6 46.2 
Response to chemotherapy n=42 
      >95 %  26 61.9 
      < 95% 16 38.1 
Surgery n=55 
      Yes 42 76.3 
      No  13 23.6 
Type of surgery   
Amputation 35 83.3 
Limb salvage 7 16.7 
*Reasons for not receiving chemotherapy: Treatment declined and for palliation from the 
onset 
 
Outcome 
The five-year overall survival (OS) for all patients was 30.3 % while the overall survival for 
patients treated with curative intent to treat was 42%. The median follow up time was 1.3 
years (IQR:  0.4 to 3.5). 
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Figure 2: Kaplan-Meier survival analysis of factors shown to have prognostic 
significance on univariate analysis 
 
As shown in Figure 2, site of primary tumour (p = 0.044) advanced stage at presentation (p = 
0.0001) and unknown LDH (p = 0.01) were shown on univariate analysis to confer 
prognostic significance. In the multivariate analysis site of tumour was not confirmed as a 
significant prognosticator (p =0.123) but unknown LDH levels were demonstrated to have 
significance.  
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TABLE 5. Risk factor analysis of children and adolescents with osteogenic sarcoma at CMJAH  
Variables 5 year 
overall 
survival 
(%) 
Hazard ratio 95% CI 
Lower 
95% CI Upper p value 
Logrank 
Sex      
     Male 34.8 Ref   0.265 
     Female 25.5 1.411 0.736 2.706  
Ethnicity      
    African 29.9 Ref   0.423 
    Other 30.5 0.737 0.358 1.521  
Body mass index (BMI)      
     BMI<18 24.3 1.793 0.858 3.746 0.165 
     BMI>18 40.9 Ref    
Site of Tumour      
     Axial 44.4 2.032 0.842 4.908 0.044 
     Appendicular 30.5 Ref    
Duration of symptoms      
     < Median 22.2 Ref 0.350 1.749 0.499 
     >Median 32.9 0.783    
Histological subtype      
     Osteoblastic 30.3 1.077 0.452 2.567 0.749 
     Chondroblastic 37.5 Ref    
     Telangiectatic 30 0.986 0.260 3.746  
Stage of tumour 
 
     
     Localised 61.0 Ref   0.0001 
 
     Metastatic 
 
41.0 3.879 
 
1.971 7.633  
Site of metastases 
 
     
     Pleuropulmonary 6.7 Ref   0.762 
 
     Skeletal 
 
0 1.102 
 
0.401 
 
3.033 
 
 
     Combination 0 0.759 
 
0.179 
 
3.214 
 
 
Size of primary tumour 
 
     
     < 8 cm 15.6 1.209 0.475 3.077 0.655 
 
     > 8 cm 32.6 Ref    
Alkaline phosphatase      
     Normal N/A N/A N/A N/A N/A 
     Elevated 30.3     
Lactate dehydrogenase      
     Normal 75.0 Ref    
     Elevated 29.9 2.855 0.631 12.914 0.011 
     Unknown  0 10.329 1.727 61.789  
Response to chemotherapy      
     >95% necrosis 52.0 Ref   0.440 
     <95% necrosis 23.6 1.361 0.598 3.098  
     Ref denotes the reference value against which other values were compared. CI: confidence interval.  
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Causes of death 
In the cohort of 55 patients, 24 patients died of disease progression while five died from 
relapsed disease. Seven of the 42 patients given chemotherapy died secondary to 
neutropaenic sepsis. One patient developed a right ventricular thrombus and one died 
secondary to doxorubicin-related dilated cardiomyopathy. The treatment-related mortality 
was thus 21. 4%. 
DISCUSSION 
This single centre, 20-year study showed that the 5-year survival rate of children with 
osteosarcoma was lower than anticipated, but higher than in similar South African series 
(5)
.  
The median duration of presenting symptoms was 90 days, a large proportion of patients 
(38.2%) presented with advanced disease and the majority had a body mass index less than 
18, a possible surrogate marker for under nutrition. All our patients presented malnourished. 
This could be due to cachexia due to disease progression or other socio-economic factors. In 
addition, most patients presented with elevated LDH and ALP, possibly reflecting the large 
size of the tumours. 
It is notable that the four patients who received doses of doxorubicin > 350mg/m
2
 developed 
cardiomyopathy secondary to doxorubicin toxicity. The safe dose of doxorubicin is now 
considered to be < 350mg/m
2
. We do not comment on other acute toxicities as the data in a 
retrospective study such as this is incomplete.  
Univariate analysis of prognostic factors demonstrated that site of primary tumour, advanced 
disease and elevated LDH were significant.
 
The finding that high LDH levels at presentation 
were associated with inferior outcomes is consistent with published literature, which suggests 
that LDH is an effective biomarker of prognosis. However, multivariate analysis confirmed 
only unknown LDH results and advanced stage as significant prognosticators. Patients who 
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did not have LDH levels recorded presented in extremis, and demised before blood tests were 
taken. 
It was not possible to assess whether an elevated alkaline phosphatase (ALP) level was 
associated with poorer outcomes as all patients presented with high ALP levels and there was 
thus no comparison group. Interestingly, delay in diagnosis and poor nutritional status were 
not shown to affect outcome adversely, as in other studies 
(16, 17)
. Many referral centres cover 
a large drainage area, including surrounding African countries and to get to a specialised unit 
most of our patients have been seen at primary health care clinics then referred to different 
level hospital before being sent to the referral or treating centre. Patients may experience 
barriers to accessing quality health care despite post-apartheid health policies designed to 
increase access to health care 
(1, 3, 5)
. These barriers may include financial shortage, and time 
constraints especially for people employed in the informal sector 
(15,16)
. 
The five-year survival rate of those treated with curative intent of only 42% can be 
considered to be low. The survival rate of 30.3% for the entire cohort, while higher than those 
in other South African series 
(5)
, still leaves a lot of room for improvement. Five year survival 
rates in high income countries range from 60-70% 
(1, 5),
 dropping to approximately 20% for 
those patients with metastatic disease. 
(5, 6, 7, 9). 
The discrepancy may in part be explained by 
the limited capacity to perform specialised surgery such as excision of multiple metastases in 
South Africa 
(1, 2, 6)
. The fact that seven patients did not receive the indicated curative 
treatment due to cultural impediments indubitably contributed to the low survival rate 
(13, 14)
.  
Parameters such as size of tumour and histological subtype, shown to have prognostic value 
in larger studies 
(3, 7)
, were not shown in this series to be significant, most likely due to the 
small numbers. As osteosarcoma is a rare condition, the number of patients included in this 
study is small.  
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Treatment-related mortality was 21.4% in this cohort and if this modifiable factor can be 
addressed, it might contribute positively to our five-year survival rate. 
Limitations 
As this was a retrospective review, data collection relied on adequacy and completeness of 
the clinical notes and data filed on the clinic database. Folders with substantially incomplete 
data represented a relatively large proportion of the study number (15.4%). Duration of 
symptoms was retrospectively calculated based on history of symptoms stated in the folder 
and may thus be inaccurate. 
 Nutritional assessment was suboptimal in this series and was based merely on BMI which is 
an incomplete indicator of nutrition especially in the paediatric population. 
Normal or healthy weight status is based on BMI between the 5
th
 and 85
th
 percentile on the 
CDC growth chart. It is difficult to provide healthy weight ranges for children and teens 
because the interpretation of BMI depends on weight, height, age, and sex. The average BMI 
is somewhere between 16 and 17 as of 2010, depending on age and gender, but the range of 
what is healthy is broader than this. 
Despite the small numbers, this is currently the largest group of paediatric patients with 
osteosarcoma reported in South Africa and indeed one of the largest in Africa. This is the 
only study that has attempted to determine the prognostic factors.  
 
 
 
 
 
 
24 
Conclusion 
Osteosarcoma, while rare, is the most common bone tumour in children and adolescents and 
has poor survival rates. Children in South Africa who presented with advanced disease or 
unknown LDH levels have higher mortality rates and the five-year overall survival rate was 
low. 
Clinicians who are aware of the early warning signs of childhood cancer may detect 
osteosarcoma when these tumours have not yet metastasised, facilitating early intervention. 
This may contribute to a rise in the survival rate and a decrease in the rate of radical 
amputations. 
Although nutritional status and duration of presenting symptoms were not shown to have 
significant prognostic implications in this small series, these modifiable factors may prove to 
have relevance in a much larger sample. 
As treatment-related mortality is responsible for more than 20% of deaths in our series, 
protocol review should be considered. 
A prospective, multi-centre study, conducted on children in low and middle income settings, 
including both the private and the public sectors, is required to determine definitively whether 
modifiable factors such as nutrition, treatment related mortality and diagnostic lag time affect 
prognosis.  
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